Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva, EVN (26/05/2022)

29.05.2022

Valneva: Valneva, an Austrian/French specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.
Valneva: weekly performance: -3.91%

EVN: Revenue recorded by Austrian utility company EVN Group rose by 65.5% to Euro 2,126.7m in the first half of 2021/22, based on a variety of individual factors: In South East Europe, the upsurge in electricity prices led to sound growth in energy distribution while weather-related volume effects were responsible for higher network revenue. In Austria, the network tariffs set by E-Control as of 1 January 2021 and 1 January 2022 had a positive influence on network revenue. Other important impulses were provided by price effects from renewable electricity generation and positive valuation effects from hedges. The more frequent use of the Theiss power plant by the Austrian transmission network operator for network stabilisation generally offset the revenue lost from the Walsum 10 power plant following the sale of EVN’s investment and the termination of electricity purchases from this source. Growth was also recorded in the international project business. EBITDA recorded by the EVN Group fell by 21.6% year-on-year to Euro 420.2m in the first half of 2021/22. Group net result for the period equalled Euro 127.4m. This represents a year-on-year decline of 27.6%.
EVN: weekly performance: 0.00%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (26/05/2022)


Partners









latest 21st Austria

21st Austria weekly - Valneva, EVN (26/05/2022)


29.05.2022, 1864 Zeichen



Valneva: Valneva, an Austrian/French specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.
Valneva: weekly performance: -3.91%

EVN: Revenue recorded by Austrian utility company EVN Group rose by 65.5% to Euro 2,126.7m in the first half of 2021/22, based on a variety of individual factors: In South East Europe, the upsurge in electricity prices led to sound growth in energy distribution while weather-related volume effects were responsible for higher network revenue. In Austria, the network tariffs set by E-Control as of 1 January 2021 and 1 January 2022 had a positive influence on network revenue. Other important impulses were provided by price effects from renewable electricity generation and positive valuation effects from hedges. The more frequent use of the Theiss power plant by the Austrian transmission network operator for network stabilisation generally offset the revenue lost from the Walsum 10 power plant following the sale of EVN’s investment and the termination of electricity purchases from this source. Growth was also recorded in the international project business. EBITDA recorded by the EVN Group fell by 21.6% year-on-year to Euro 420.2m in the first half of 2021/22. Group net result for the period equalled Euro 127.4m. This represents a year-on-year decline of 27.6%.
EVN: weekly performance: 0.00%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (26/05/2022)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #653: ATX TR Pfingstmontag erneut auf Rekord, den DAX year to date überholt, Tipp von Andi Gross für Agrana




 

Bildnachweis

Aktien auf dem Radar:E.ON , Rosenbauer, EVN, FACC, Amag, Flughafen Wien, Austriacard Holdings AG, Rosgix, Erste Group, Telekom Austria, voestalpine, SBO, Österreichische Post, Strabag, CA Immo, Immofinanz, Wolford, Wolftank-Adisa, Marinomed Biotech, Agrana, OMV, Uniqa, VIG, Wienerberger.


Random Partner

Wiener Privatbank
Die Wiener Privatbank ist eine unabhängige Privatbank mit Sitz in Wien, deren Anspruch darin liegt, die besten Investmentchancen am globalen Markt für ihre Kunden zu identifizieren. Zu den Kunden zählen Family Offices, Privatinvestoren, Institutionen sowie Stiftungen im In- und Ausland.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten